EP1648569A1 - Cosmetic use of a composition containing at least one oxazoline, serving as an active substance, as a slimming product and/or for preventing and/or treating cellulite - Google Patents
Cosmetic use of a composition containing at least one oxazoline, serving as an active substance, as a slimming product and/or for preventing and/or treating celluliteInfo
- Publication number
- EP1648569A1 EP1648569A1 EP04767366A EP04767366A EP1648569A1 EP 1648569 A1 EP1648569 A1 EP 1648569A1 EP 04767366 A EP04767366 A EP 04767366A EP 04767366 A EP04767366 A EP 04767366A EP 1648569 A1 EP1648569 A1 EP 1648569A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- oxazoline
- composition
- cosmetic
- type
- oxazolines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 239000002537 cosmetic Substances 0.000 title claims abstract description 31
- 239000013543 active substance Substances 0.000 title claims abstract description 19
- 208000035484 Cellulite Diseases 0.000 title claims abstract description 18
- 206010049752 Peau d'orange Diseases 0.000 title claims abstract description 18
- 230000036232 cellulite Effects 0.000 title claims abstract description 16
- 125000003504 2-oxazolinyl group Chemical group O1C(=NCC1)* 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 12
- 150000002918 oxazolines Chemical class 0.000 claims description 19
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000002366 lipolytic effect Effects 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 230000008030 elimination Effects 0.000 claims description 5
- 238000003379 elimination reaction Methods 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- FREPJBZLNPPGDM-UHFFFAOYSA-N 4,4-dimethyl-2-undecyl-5h-1,3-oxazole Chemical compound CCCCCCCCCCCC1=NC(C)(C)CO1 FREPJBZLNPPGDM-UHFFFAOYSA-N 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- RSDFPCQESXIWFY-UHFFFAOYSA-N (2-heptadecyl-4-methyl-5h-1,3-oxazol-4-yl)methanol Chemical compound CCCCCCCCCCCCCCCCCC1=NC(C)(CO)CO1 RSDFPCQESXIWFY-UHFFFAOYSA-N 0.000 claims description 2
- VBFBQEURBQANIX-UHFFFAOYSA-N (4-ethyl-2-undecyl-5h-1,3-oxazol-4-yl)methanol Chemical compound CCCCCCCCCCCC1=NC(CC)(CO)CO1 VBFBQEURBQANIX-UHFFFAOYSA-N 0.000 claims description 2
- JMQRHKPPXPCTGP-UHFFFAOYSA-N (4-methyl-2-undecyl-5h-1,3-oxazol-4-yl)methanol Chemical compound CCCCCCCCCCCC1=NC(C)(CO)CO1 JMQRHKPPXPCTGP-UHFFFAOYSA-N 0.000 claims description 2
- CHAMUCPNQGNBLJ-VAWYXSNFSA-N 2-[(e)-heptadec-8-enyl]-4,4-dimethyl-5h-1,3-oxazole Chemical compound CCCCCCCC\C=C\CCCCCCCC1=NC(C)(C)CO1 CHAMUCPNQGNBLJ-VAWYXSNFSA-N 0.000 claims description 2
- HCIRJRYSFLWMMS-ZHACJKMWSA-N [2-[(e)-heptadec-8-enyl]-4-methyl-5h-1,3-oxazol-4-yl]methanol Chemical compound CCCCCCCC\C=C\CCCCCCCC1=NC(C)(CO)CO1 HCIRJRYSFLWMMS-ZHACJKMWSA-N 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 230000001643 venotonic effect Effects 0.000 claims description 2
- 210000001789 adipocyte Anatomy 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 150000002632 lipids Chemical class 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 150000004665 fatty acids Chemical class 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 150000003626 triacylglycerols Chemical class 0.000 description 9
- 239000000284 extract Substances 0.000 description 8
- 230000004132 lipogenesis Effects 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 230000004130 lipolysis Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108010073771 Soybean Proteins Proteins 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 229940001941 soy protein Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 244000194101 Ginkgo biloba Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000007957 coemulsifier Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- -1 polyol esters Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000208983 Arnica Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- 241000167550 Centella Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 240000008669 Hedera helix Species 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 241000605385 Ruscus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 235000002254 Viola papilionacea Nutrition 0.000 description 2
- 244000225942 Viola tricolor Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 229940011399 escin Drugs 0.000 description 2
- 229930186222 escin Natural products 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 150000002515 isoflavone derivatives Chemical class 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- XOMRRQXKHMYMOC-NRFANRHFSA-N (3s)-3-hexadecanoyloxy-4-(trimethylazaniumyl)butanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H](CC([O-])=O)C[N+](C)(C)C XOMRRQXKHMYMOC-NRFANRHFSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 244000228088 Cola acuminata Species 0.000 description 1
- 235000010205 Cola acuminata Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 235000016622 Filipendula ulmaria Nutrition 0.000 description 1
- 244000061544 Filipendula vulgaris Species 0.000 description 1
- 241000227647 Fucus vesiculosus Species 0.000 description 1
- 244000119461 Garcinia xanthochymus Species 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 208000013262 Localized lipodystrophy Diseases 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241001184198 Orthosiphon Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Chemical class 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 108010081750 Reticulin Proteins 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 240000005746 Ruta graveolens Species 0.000 description 1
- 235000001347 Ruta graveolens Nutrition 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- 208000031439 Striae Distensae Diseases 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 240000000785 Tagetes erecta Species 0.000 description 1
- 244000071378 Viburnum opulus Species 0.000 description 1
- 235000019013 Viburnum opulus Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 229920000800 acrylic rubber Polymers 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000010477 apricot oil Substances 0.000 description 1
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- YFUNDTIYMJBNTB-UHFFFAOYSA-N aziridin-1-ylphosphane Chemical compound PN1CC1 YFUNDTIYMJBNTB-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940059958 centella asiatica extract Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 239000008308 lipophilic cream Substances 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- PRAUVHZJPXOEIF-AOLYGAPISA-N madecassic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PRAUVHZJPXOEIF-AOLYGAPISA-N 0.000 description 1
- 229940011656 madecassic acid Drugs 0.000 description 1
- BUWCHLVSSFQLPN-UHFFFAOYSA-N madecassic acid Natural products CC1CCC2(CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(=O)O)C2C1C)C(=O)OC6OC(COC7OC(CO)C(OC8OC(C)C(O)C(O)C8O)C(O)C7O)C(O)C(O)C6O BUWCHLVSSFQLPN-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000010702 perfluoropolyether Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 239000001229 ruta graveolens Substances 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028201 sequestering of triglyceride Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
Definitions
- composition comprising at least one oxazoline, as active principle, as slimming agent and / or for preventing and / or treating cellulite
- the present invention relates to the use of a cosmetic composition with slimming action, comprising, as active principle, at least one oxazoline.
- the present invention also relates to the use of such a composition for preventing and or treating cellulite.
- Thinning in the context of the present invention preferably takes place by combating localized overweight.
- Adiposity or excess fat in the subcutaneous cellular tissue, can have many more or less complex causes, more or less known or more or less understood.
- Adipose tissue a particular variety of connective tissue, consists of adipocytes, separated by partitions, which are themselves delimited by conjunctivovascular spans. The connective part contains collagen fibers, reticulin and reticuloendothelial cells.
- Adipocytes contain variable amounts of fat in the form of triglycerides, these triglycerides being synthesized in vivo by the adipocytes themselves, according to enzymatic type reactions from free fatty acids and glycerol, product of degradation of glucose, contained in the body and brought to it by food.
- the triglycerides thus formed and then stored in the adipocyte cells can also redecompose, always under the action of specific enzymes contained in these same cells, this time releasing fatty acids on the one hand and glycerol and / or mono- and / or di-esters of glycerol on the other hand.
- the fatty acids thus released can then either diffuse in the body to be consumed or transformed in different ways, or be recaptured, immediately or a little later, by the adipocytes to generate triglycerides again.
- Fat cells therefore store calories from food in the form of triglycerides and then transform them into free fatty acids using enzyme systems.
- Adipocytes which thus play an essential role in the synthesis of lipids, their storage and their release in the blood, are regulated by lipogenesis, which corresponds to the formation of triglycerides by enzymatic reaction between fatty acids and glycerol from glucose, and lipolysis, which corresponds to enzymatic decomposition triglycerides into fatty acids and glycerol.
- mediators such as adrenaline, estrogens, which will block or not the lipids within the adipocytes, alpha receptors, which block lipolysis, and beta receptors, which facilitate lipolysis.
- Cellulite or localized lipodystrophy, is characterized by an oedematous infiltration of adipose tissue which alters the aesthetics and the harmony of the silhouette.
- triglycerides results in particular from storage of triglycerides in adipocytes, which can increase in volume considerably, indeed, these cells can reach, depending on the circumstances, 40 ⁇ m to 120 ⁇ m in diameter, an increase of 27 times in volume, and an increase in the viscosity of the fundamental substance of the dermis, which results in water retention and a decrease in cellular exchanges. These two mechanisms cause compression of the blood and lymphatic vessels and congestion of the tissues.
- Lipolytics act on the elimination of lipid overloads (lipolysis) and liporeducing agents fight against the formation of fat (lipogenesis).
- active ingredients are most often administered topically, but they can also be administered orally.
- disinfiltrating active ingredients such as virbunum, wild pansy, and veinotonics, such as ruscus, Pescine, which are often associated with slimming active ingredients.
- formulations comprising these known slimming and / or anti-cellulite active agents can be supplemented by restructuring and smoothing active agents which fight against sagging skin.
- the field of cosmetics is constantly looking for new molecules or new extracts that are effective in combating human or animal adiposity, with a view in particular to obtaining a general, or on the contrary localized, effect of slimming and / or refinement of the skin or the silhouette.
- the Applicant thus describes a medicament, comprising at least one oxazoline as active ingredient, intended for the treatment or prevention of allergic, and / or inflammatory, and / or irritative reactions of the skin and or mucous membranes.
- compositions comprising oxazolines, in which the oxazolines are promoters of penetration of physiological active agents through the stratum corneum layer of the skin.
- oxazolines are also capable of inhibiting lipogenesis in human adipocytes.
- composition comprising at least one oxazoline, as active ingredient, can be used as a slimming composition, and / or to prevent and / or treat cellulite.
- Ri represents a C ⁇ -C 0 alkyl group, linear or branched, saturated or unsaturated, optionally comprising one or more ethylenic unsaturation (s) as well as one or more substituent (s) chosen from the group formed by hydroxy (OH) and C ⁇ -C 6 alkoxy (OC- .
- R 2 , R 3 , R t and R 5 independently represent a hydrogen atom, a hydroxy radical, or a linear or branched, saturated or unsaturated - C 0 alkyl group, optionally comprising one or more unsaturations ethylene and one or more substituent (s) selected (s) from the group formed by hydroxyl (OH), alkoxy, C ⁇ -C 6 (OC ⁇ -C 6) alkoxy C ⁇ -C 6 carbonyl (t COOC- -C 6 ).
- alkoxy, C ⁇ -C 6 (OC ⁇ -C 6) is meant within the meaning of the present invention, an alkoxy radical whose alkyl moiety comprises 1 to 6 carbon atoms.
- said oxazoline is a type 1 oxazoline selected from the group consisting of 2-undecyl-4- hydroxymethyl-4-methyl-1,3-oxazoline, 2-undecyl-4,4-dimethyl-1,3-oxazoline, (E) -4,4-dimethyl-2-heptadec-8-enyl- 1,3-oxazoline, 4-hydroxymethyl-4-methyl-2-heptadecyl- 1,3-oxazoline, (E) -4-hydroxymethyl-4-methyl-2-heptadec-8-enyl-1,3 - oxazoline, 2-undecyl-4-ethyl-4-hydroxymethyl-1,3-oxazoline.
- the so-called oxazoline is 2-undecyl-4,4-dimethyl-1,3-oxazoline, called OX100, of formula:
- the expression “thinning” or “fight against localized overweight”, is meant according to the present invention an action making it possible to avoid or at least reduce the formation of subcutaneous fats as described above. This action is reflected in particular by a reduction in unsightly overloads or reserves, by a refinement of the silhouette, by an acceleration of the elimination of surpluses, by a better definition of the body contour or even a resculpted silhouette.
- cosmetic treatment for combating localized overweight means, according to the present invention, the use of a cosmetic treatment making it possible to visibly measure the action described above.
- a topical composition comprising one or more oxazolines used according to the invention can be applied to the areas of the skin capable of forming these localized overweight, namely areas where these overloads are already formed or being formed.
- the cosmetic composition according to the invention is characterized in that the oxazoline concentration is advantageously between approximately 0.01 and approximately 10% by weight, and more advantageously between approximately 0.01 and approximately 3% by weight, relative to the weight total of the composition.
- composition which allows the implementation of the invention comprises a cosmetically acceptable support, that is to say a support compatible with the skin and can be in all the galenical forms normally used for a topical application, in particular in the form of an aqueous, hydroalcoholic or oily solution, an oil-in-water or water-in-oil or multiple emulsion, an aqueous or oily gel, a liquid, pasty or solid anhydrous product, a dispersion of oil in an aqueous phase using spherules, these spherules possibly being polymeric nanoparticles such as nanospheres and nanocapsules or better lipid vesicles of ionic and / or nonionic type, of a trans-dermal or sub-dermal device any other form for topical application.
- a cosmetically acceptable support that is to say a support compatible with the skin and can be in all the galenical forms normally used for a topical application, in particular in the form of an aqueous, hydroalcoholic or oil
- This composition can be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foam. or a gel. It can optionally be applied to the skin in the form of an aerosol. It can also be in solid form, and for example in the form of a stick. It can also be applied using a patch.
- the cosmetically acceptable medium is an oily solution, a water-in-oil emulsion, an oil-in water emulsion, a microemulsion, an oily gel, an anhydrous gel, a dispersion of vesicles, microcapsules or microparticles, a device transdermal
- the composition according to the invention can also contain the adjuvants usual in the cosmetic field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, thickeners, preservatives, antioxidants, solvents, perfumes, chelating agents, odor absorbers, chemical or mineral filters, mineral pigments, surfactants, polymers, silicone oils and coloring materials.
- these various adjuvants are those conventionally used in the fields under consideration, and for example from 0.01 to 20% of the total weight of the composition.
- These adjuvants depending on their nature, can be introduced into the fatty phase, into the aqueous phase, into the lipid vesicles and or into the nanoparticles.
- the proportion of the fatty phase can range from 5 to 80% by weight, and preferably from 5 to 50% of the total weight of the composition.
- the oils, emulsifiers and coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the field under consideration.
- the emulsifier and the coemulsifier are present in the composition in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% of the total weight of the composition.
- emulsifiers and coemulsifiers which can be used in the invention, there may be mentioned, for example, fatty acid and polyethylene glycol esters such as PEG-40 stearate, PEG-100 stearate, fatty acid and polyol esters such as glyceryl stearate and sorbitan tristearate.
- hydrophilic gelling agents mention may in particular be made of carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate / alkyl acrylate copolymers, polyacrylamides, polysaccharides, natural gums and clays, and, as lipophilic gelling agents, quote clays modified such as bentones, metal salts of fatty acids, hydrophobic silica and polyethylenes.
- the optimal modes of administration, the dosages and the galenical forms of the compounds and compositions according to the invention can be determined according to the criteria generally taken into account in the establishment of a cosmetic treatment, preferably dermatological, adapted to a patient as for example the patient's body weight, the excess fat observed, the appearance of the cellulite tissue, the tolerance to treatment, the type of skin.
- a cosmetic treatment preferably dermatological, adapted to a patient as for example the patient's body weight, the excess fat observed, the appearance of the cellulite tissue, the tolerance to treatment, the type of skin.
- composition used according to the invention may contain other active ingredients with a slimming action such as lipolytics and liporeducing agents as described in the introduction, leading to a complementary or possibly synergistic effect.
- the invention thus relates to the use of oxazolines for the preparation of topical compositions useful for preventing and / or treating cellulite and / or for promoting thinning and in particular for combating localized overweight, characterized in that one or more oxazolines as well as one or more slimming active agents of lipolytic type and / or one or more slimming active agents of liporeducing type are applied simultaneously, separately or spread over time.
- the lipolytic type slimming active can be chosen from: caffeine, rhodysterol, palmitoyl-carnitine, bioactives alpha and gamma, escin, ginkgo biloba and sphingosine.
- the slimming active ingredient of the liporeducing type can be chosen from: andiroba, Garcinia Cambogia, rutin.
- disinfiltrating and / or veinotonic active agents can be chosen from: viburnum, ivy, arnica, pisolle, wild pansy, Fucus vesiculosus, ruscus, ginkgo biloba and escin.
- composition used according to the invention can also comprise other active agents such as: - An extract of sophora japonica flowers: this extract is rich in flavonoids (anti-radical) and rutin. This active ingredient promotes microcirculation, facilitating and activating the drainage and disinfiltration of tissues;
- Centella asiatica extract Centella extract, a plant native to East Africa and Madagascar.
- This active ingredient contains terpenes (asiaticosides, asiatica acid and madecassic acid), with draining, disinfiltrating and firming properties on the tissues. It is used in particular in slimming products but also in anti-stretch mark, anti-wrinkle and healing products; 0 to 5% of centella extract can thus be present in a slimming composition; - "Hydrolyzed Soy Protein”: soy protein which is an elastoregulator.
- soy peptides can be any peptide obtained by hydrolysis of proteins extracted from soy, according to operating conditions known to those skilled in the art, in other words any soy protein hydrolyzate.
- the soy peptides which are described in patent application WO 00/19974, are particularly suitable for being introduced into the compositions used in the context of the present invention.
- This active ingredient allows the restoration of cell renewal mechanisms, activates the synthesis of structural elements of the extracellular matrix and has a restructuring, regenerating and firming action; 0 to 5% of soy protein can thus be present in a slimming composition; - anti-aging and / or firming active ingredients, among which mention may be made of avocado furans, retinol and its derivatives, vitamin C, vitamin E, silicon, or soy unsaponifiable matter, etc .;
- - antioxidants capable of blocking the differentiation of pre-adipocytes into adipocytes, in particular triterpenes, PPARs antagonists (Peroxysome Proliferator-Activated Receptor), MMPs inhibitors, in particular the lupine peptide extract as described in the French patent application FR 2,792,202;
- active agents capable of blocking the differentiation of pre-adipocytes into adipocytes in particular triterpenes, PPARs antagonists (Peroxysome Proliferator-Activated Receptor), MMPs inhibitors, in particular the lupine peptide extract as described in the French patent application FR 2,792,202;
- the present invention also relates to a cosmetic treatment method for promoting thinning, characterized in that a cosmetic composition comprising one or more oxazolines is applied topically.
- Another object of the present invention is a cosmetic treatment method for preventing and / or treating cellulite, characterized in that a composition comprising one or more oxazolines is applied topically.
- An object of the present invention is also a cosmetic treatment method for refining the silhouette, accelerating the elimination of excess, better defining, the outline of the body and / or resculpting the silhouette, characterized in that it is applied topically.
- a composition comprising one or more oxazolines.
- Overweight is characterized, in the context of the present invention, by being overweight, relative to the "ideal weight", not pathological.
- the cosmetic treatment according to the invention makes it possible to lose or refine superfluous localized curves but is not identified with a therapeutic treatment.
- one or more is applied topically to the areas of the skin liable to form localized overweight, simultaneously, prepared or spread over time.
- oxazolines as well as one or more slimming active agents of lipolytic and / or liporeductive type, and / or one or more disinfiltrating and / or venotonic active agents.
- Figures 1 and 2 illustrate the effect of OXlOO on the incorporation of radiolabelled acetate into adipocyte lipids. The results are expressed as a percentage of the control and represent the incorporation of radiolabelled acetate.
- Example 1 oil in water cream
- the suspension of adipocytes is then rinsed and diluted three times in the culture medium.
- the culture medium consists of:
- the adipocytes in suspension are incubated for 1 hour at 37 ° C. in the presence of different concentrations of OXlOO.
- the OX100 concentrations tested are
- the OXlOO does not induce any interference with radiolabelling.
- OXlOO at 20 and 4 ⁇ M reduces acetate inco ⁇ oration by 31 and 25% respectively of the control (FIG. 1) It has been shown quite unexpectedly that OXlOO is capable of inhibiting lipogenesis in adipocytes humans.
- the adipocytes in suspension are incubated for 1 h at 37 ° C. in the presence of different concentrations of OX100 (10, 20 and 100 ⁇ M).
- a volume of 10 ml of radiolabelled acetate (2-C 14 , 60.87 ⁇ Ci / ml, Amersham) is then added to the preparation.
- the lipids are extracted according to the procedure described by Bligh and Dyer (methanol / chloroform / water), evaporated under nitrogen and the inco ⁇ orated radioactivity was quantified by liquid scintillation (LKB 1210 Rackbeta).
- ceralin Fatty Acid Synthase
- OXlOO has shown significant inhibitory activity on lipid synthesis. OXlOO is therefore capable of inhibiting lipogenesis in human adipocytes in culture.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the cosmetic use of a composition containing at least one oxazoline, serving as an active substance, as a slimming product, and to an associated cosmetic treatment method. The invention also relates to the cosmetic use of a composition containing at least one oxazoline, serving as an active substance, for preventing and/or treating cellulite.
Description
Utilisation cosmétique d'une composition comprenant au moins une oxazoline, à titre de principe actif, comme amincissant et/ou pour prévenir et/ou traiter la celluliteCosmetic use of a composition comprising at least one oxazoline, as active principle, as slimming agent and / or for preventing and / or treating cellulite
La présente invention se rapporte à l'utilisation d'une composition cosmétique à action amincissante, comprenant, à titre de principe actif, au moins une oxazoline. La présente invention se rapporte également à l'utilisation d'une telle composition pour prévenir et ou traiter la cellulite.The present invention relates to the use of a cosmetic composition with slimming action, comprising, as active principle, at least one oxazoline. The present invention also relates to the use of such a composition for preventing and or treating cellulite.
L'amincissement dans le cadre de la présente invention passe préférentiellemerit par la lutte contre la surcharge pondérale localisée.Thinning in the context of the present invention preferably takes place by combating localized overweight.
L'adiposité, ou excès de graisse dans le tissu cellulaire sous-cutané, peut avoir de nombreuses causes plus ou moins complexes, plus ou moins connues ou plus ou moins comprises. Le tissu adipeux, variété particulière de tissu conjonctif, est constitué d' adipocytes, séparés par des cloisons, elles-mêmes délimitées par des travées conjonctivovasculaires. La partie conjonctive comporte des fibres de collagènes, de réticuline et des cellules réticulo-endothéliales.Adiposity, or excess fat in the subcutaneous cellular tissue, can have many more or less complex causes, more or less known or more or less understood. Adipose tissue, a particular variety of connective tissue, consists of adipocytes, separated by partitions, which are themselves delimited by conjunctivovascular spans. The connective part contains collagen fibers, reticulin and reticuloendothelial cells.
Les adipocytes contiennent des quantités variables de graisses sous la forme de triglycérides, ces triglycérides étant synthétisés in vivo par les adipocytes eux-mêmes, selon des réactions de type enzymatique à partir des acides gras libres et du glycérol, produit de dégradation du glucose, contenus dans l'organisme et apportés à celui-ci par l'alimentation. Or, parallèlement, les triglycérides ainsi formés, puis stockés, dans les cellules adipocytes peuvent également se redécomposer, toujours sous l'action d'enzymes spécifiques contenues dans ces mêmes cellules, en libérant cette fois des acides gras d'une part et du glycérol et/ou des mono- et/ou des di-esters du glycérol d'autre part. Les acides gras ainsi relargués peuvent alors soit diffuser dans l'organisme pour y être consommés ou transformés de différentes façons, soit être recaptés, aussitôt ou un peu plus tard, par les adipocytes pour générer à nouveau des triglycérides. Les adipocytes emmagasinent donc les calories d'origine alimentaire sous forme de triglycérides puis les transforment en acides gras libres en faisant appel à des systèmes enzymatiques. Les adipocytes, qui jouent ainsi un rôle essentiel dans la
synthèse des lipides, leur stockage et leur libération dans le sang, sont régulées par la lipogénèse, qui correspond à la formation de triglycérides par réaction enzymatique entre des acides gras et le glycérol provenant du glucose, et la lipolyse, qui correspond à la décomposition enzymatique de triglycérides en acides gras et glycérol. Ces transformations se réalisent notamment sous le contrôle de médiateurs tels que l'adrénaline, les oestrogènes, qui vont bloquer ou non les lipides au sein des adipocytes, les récepteurs alpha, qui bloquent la lipolyse, et les récepteurs bêta, qui facilitent la lipolyse.Adipocytes contain variable amounts of fat in the form of triglycerides, these triglycerides being synthesized in vivo by the adipocytes themselves, according to enzymatic type reactions from free fatty acids and glycerol, product of degradation of glucose, contained in the body and brought to it by food. However, at the same time, the triglycerides thus formed and then stored in the adipocyte cells can also redecompose, always under the action of specific enzymes contained in these same cells, this time releasing fatty acids on the one hand and glycerol and / or mono- and / or di-esters of glycerol on the other hand. The fatty acids thus released can then either diffuse in the body to be consumed or transformed in different ways, or be recaptured, immediately or a little later, by the adipocytes to generate triglycerides again. Fat cells therefore store calories from food in the form of triglycerides and then transform them into free fatty acids using enzyme systems. Adipocytes, which thus play an essential role in the synthesis of lipids, their storage and their release in the blood, are regulated by lipogenesis, which corresponds to the formation of triglycerides by enzymatic reaction between fatty acids and glycerol from glucose, and lipolysis, which corresponds to enzymatic decomposition triglycerides into fatty acids and glycerol. These transformations are carried out in particular under the control of mediators such as adrenaline, estrogens, which will block or not the lipids within the adipocytes, alpha receptors, which block lipolysis, and beta receptors, which facilitate lipolysis.
La cellulite, ou lipodystrophie localisée, est caractérisée par une infiltration oedémateuse du tissu adipeux qui altère l'esthétique et l'harmonie de la silhouette.Cellulite, or localized lipodystrophy, is characterized by an oedematous infiltration of adipose tissue which alters the aesthetics and the harmony of the silhouette.
Si, pour des raisons diverses, telles qu'une nourriture trop riche, l'inactivité et/ou le vieillissement, un déséquilibre substantiel s'installe dans l'organisme entre la lipogénèse et la lipolyse, c'est à dire plus précisément si les quantités de graisses formées par lipogénèse deviennent notablement et constamment supérieures à celles qui sont éliminées par lipolyse, il se produit alors dans les adipocytes une accumulation de triglycérides, qui, si elle devient excessive, peut se traduire par une surcharge pondérale localisée et/ou progressivement par l'apparition d'une peau épaisse, à surface souvent irrégulière, d'aspect dit "peau d'orange", et de consistance plus ou moins flasque ou gélatineuse, donnant finalement à la silhouette un aspect général disgracieux. Ce tissu cellulitique n'épargne pas les hommes mais est nettement plus fréquent chez les femmes, qu'elles soient minces ou rondes. Les masses graisseuses se localisent préférentiellement sur la moitié inférieure du corps, au niveau des hanches, des cuisses, du ventre, sans oublier les genoux et les chevilles.If, for various reasons, such as too rich food, inactivity and / or aging, a substantial imbalance is established in the body between lipogenesis and lipolysis, that is to say more precisely if the amounts of fat formed by lipogenesis become significantly and constantly higher than those which are eliminated by lipolysis, there then occurs in adipocytes an accumulation of triglycerides, which, if it becomes excessive, can result in a localized overweight and / or gradually by the appearance of thick skin, often with an irregular surface, of so-called "orange peel" appearance, and of a more or less flaccid or gelatinous consistency, finally giving the silhouette an unsightly general appearance. This cellulite tissue does not spare men but is much more common in women, whether they are thin or round. The fatty masses are localized preferentially on the lower half of the body, at the level of the hips, the thighs, the belly, without forgetting the knees and the ankles.
La cellulite résulte notamment d'un stockage des triglycérides dans les adipocytes, qui peuvent augmenter de volume de façon considérable, en effet, ces cellules peuvent atteindre, selon les circonstances, 40 μm à 120 μm de diamètre, soit une augmentation de 27 fois en volume, et d'une augmentation de la viscosité de la substance fondamentale du derme, qui se traduit par une rétention d'eau et une diminution des échanges cellulaires. Ces deux mécanismes entraînent une compression des vaisseaux sanguins et lymphatiques et une congestion des tissus. Pour prévenir la cellulite, il faut notamment : - diminuer la formation de triglycérides, c'est-à-dire diminuer la lipogénèse ; et/ou
- augmenter la lipolyse ; et/ouCellulite results in particular from storage of triglycerides in adipocytes, which can increase in volume considerably, indeed, these cells can reach, depending on the circumstances, 40 μm to 120 μm in diameter, an increase of 27 times in volume, and an increase in the viscosity of the fundamental substance of the dermis, which results in water retention and a decrease in cellular exchanges. These two mechanisms cause compression of the blood and lymphatic vessels and congestion of the tissues. To prevent cellulite, you must in particular: - reduce the formation of triglycerides, that is to say reduce lipogenesis; and or - increase lipolysis; and or
- restaurer une microcirculation active et régulière ; et/ou- restore active and regular microcirculation; and or
- limiter les oedèmes.- limit edema.
Compte tenu du profond inconfort tant physique qu'esthétique, et parfois psychologique, qu'elles occasionnent auprès des individus qui en sont atteints, en particulier chez les femmes, la surcharge pondérale localisée et la cellulite constituent de nos jours des affections de moins en moins bien supportées ou acceptées.Given the deep discomfort, both physical and aesthetic, and sometimes psychological, that they cause for individuals who are affected, especially in women, localized overweight and cellulite are nowadays less and less affections well supported or accepted.
Des méthodes ont déjà été proposées en vue de traiter la surcharge pondérale localisée et là cellulite, parmi celles-ci certaines, reposant sur des traitements chirurgicaux, tels que la liposuccion, permettent actuellement d'obtenir des résultats véritablement satisfaisants. Toutefois, de tels traitements présentent bien évidemment comme inconvénient majeur de nécessiter la mise en oeuvre sur le corps humain ou animal d'opérations invasives par nature, délicates, non sans risques et souvent coûteuses. II existe également sur le marché de nombreux cosmétiques amincissants et /ou qui ont une action anti-cellulite. Comme exemples d'actifs fréquemment utilisés, on peut notamment citer les extraits végétaux, tels que les extraits de caféine, de Gingko biloba, de reine-des-prés, de Centalla asiatica, d'arnica, de noix de cola, du fracon, du lierre grimpant,- de romarin, de souci, de ginseng, de millepertuis, d'orthosiphon, d'algues brunes, d'algues rouges, de bouleau, ... qui sont des agents lipolytiques et la sphingosine et la ratine, extrait de Ruta graveolens, qui sont des agents liporéducteurs.Methods have already been proposed for treating localized overweight and there cellulite, among these certain, based on surgical treatments, such as liposuction, currently allow to obtain truly satisfactory results. However, such treatments obviously have the major drawback of requiring the implementation on the human or animal body of invasive operations by nature, delicate, not without risks and often costly. There are also many slimming cosmetics and / or on the market which have an anti-cellulite action. As examples of frequently used active agents, mention may in particular be made of plant extracts, such as caffeine extracts, of Gingko biloba, of meadowsweet, of Centalla asiatica, of arnica, of cola nut, of the fracon, climbing ivy, - rosemary, marigold, ginseng, St. John's wort, orthosiphon, brown algae, red algae, birch, ... which are lipolytic agents and sphingosine and terry, extract of Ruta graveolens, which are liporeducing agents.
Les lipolytiques agissent au niveau de F élimination des surcharges lipidiques (lipolyse) et les liporéducteurs luttent contre la formation de graisse (lipogénèse).Lipolytics act on the elimination of lipid overloads (lipolysis) and liporeducing agents fight against the formation of fat (lipogenesis).
Ces actifs sont le plus souvent administrés par voie topique, mais ils peuvent aussi être admonistrés per os.These active ingredients are most often administered topically, but they can also be administered orally.
A ces actifs spécifiques, peuvent s'ajouter des actifs désinfiltrants. tels que le virbunum, la pensée sauvage, et des veinotoniques, tels que le ruscus, Pescine, qui sont souvent associés aux actifs amincissants.To these specific active ingredients can be added disinfiltrating active ingredients. such as virbunum, wild pansy, and veinotonics, such as ruscus, Pescine, which are often associated with slimming active ingredients.
Enfin, les formulations comprenant ces actifs amincissants et/ou anti-cellulite connus peuvent être complétées par des actifs restructurant et lissant qui luttent contre le relâchement de la peau.
Le domaine de la cosmétique est perpétuellement à la recherche de nouvelles molécules ou de nouveaux extraits efficaces pour lutter contre l'adiposité humaine ou animale, et ceci en vue notamment d'obtenir un effet général, ou au contraire localisé, d'amincissement et/ou d'affinement de la peau ou de la silhouette.Finally, the formulations comprising these known slimming and / or anti-cellulite active agents can be supplemented by restructuring and smoothing active agents which fight against sagging skin. The field of cosmetics is constantly looking for new molecules or new extracts that are effective in combating human or animal adiposity, with a view in particular to obtaining a general, or on the contrary localized, effect of slimming and / or refinement of the skin or the silhouette.
Dans sa demande de brevet f ançaise n° 01/16917, la Demanderesse décrit l'utilisation d'oxazolines, qui permettent l'inhibition de la migration des cellules de Langerhans.In its French patent application No. 01/16917, the Applicant describes the use of oxazolines, which allow the inhibition of the migration of Langerhans cells.
La Demanderesse décrit ainsi un médicament, comprenant au moins une oxazoline en tant que principe actif, destiné au traitement ou à la prévention des réactions allergiques, et/ou inflammatoires, et/ou irritatives de la peau et ou des muqueuses.The Applicant thus describes a medicament, comprising at least one oxazoline as active ingredient, intended for the treatment or prevention of allergic, and / or inflammatory, and / or irritative reactions of the skin and or mucous membranes.
La demande de brevet US 4 876 249 décrit des compositions comprenant des oxazolines, dans lesquelles les oxazolines sont des promoteurs de pénétration d'agents actifs physiologiques à travers la couche stratum corneum de la peau.The patent application US 4 876 249 describes compositions comprising oxazolines, in which the oxazolines are promoters of penetration of physiological active agents through the stratum corneum layer of the skin.
D'une manière surprenante, la Demanderesse a découvert que les oxazolines sont également capables d'inhiber la lipogénèse dans des adipocytes humains.Surprisingly, the Applicant has discovered that oxazolines are also capable of inhibiting lipogenesis in human adipocytes.
La Demanderesse a ainsi découvert qu'une composition comprenant au moins une oxazoline, à titre de principe actif, peut être utilisée en tant que composition amincissante, et/ou pour prévenir et/ou traiter la cellulite.The Applicant has thus discovered that a composition comprising at least one oxazoline, as active ingredient, can be used as a slimming composition, and / or to prevent and / or treat cellulite.
Les oxazolines selon la présente invention répondent aux formules générales suivantes:* The oxazolines according to the present invention correspond to the following general formulas: *
Type 1
Type 1
Type 2Type 2
Type 3Type 3
dans laquelle Ri représente un groupe alkyle en Cι-C 0, linéaire ou ramifié, saturé ou insaturé, comprenant éventuellement une ou plusieurs insaturation(s) éthylénique(s) ainsi que un ou plusieurs substituant(s) choisi(s) dans le groupe formé par les radicaux hydroxy (OH) et alcoxy en Cι-C6 (OC-.-C6) ; R2, R3, Rt et R5 représentent, de manière indépendante, un atome d'hydrogène, un radical hydroxy, ou un groupe alkyle en - C 0, linéaire ou ramifié, saturé ou insaturé, comprenant éventuellement une ou plusieurs insaturations éthyléniques ainsi que un ou plusieurs substituant(s) choisi(s) dans le groupe formé par les radicaux hydroxy (OH), alcoxy en Cι-C6 (OCι-C6) et alcoxy en Cι-C6 carbonyles (COOC-t-C6). Par le terme de "alcoxy en Cι-C6 (OCι-C6)", on entend au sens de la présente invention, un radical alcoxy dont le groupement alkyle comprend de 1 à 6 atomes de carbone.in which Ri represents a Cι-C 0 alkyl group, linear or branched, saturated or unsaturated, optionally comprising one or more ethylenic unsaturation (s) as well as one or more substituent (s) chosen from the group formed by hydroxy (OH) and Cι-C 6 alkoxy (OC- . -C 6 ) radicals; R 2 , R 3 , R t and R 5 independently represent a hydrogen atom, a hydroxy radical, or a linear or branched, saturated or unsaturated - C 0 alkyl group, optionally comprising one or more unsaturations ethylene and one or more substituent (s) selected (s) from the group formed by hydroxyl (OH), alkoxy, Cι-C 6 (OCι-C 6) alkoxy Cι-C 6 carbonyl (t COOC- -C 6 ). By the term "alkoxy, Cι-C 6 (OCι-C 6)" is meant within the meaning of the present invention, an alkoxy radical whose alkyl moiety comprises 1 to 6 carbon atoms.
Selon un mode avantageux de la présente invention, la dite oxazoline est une oxazoline de type 1 sélectionnée dans le groupe composé de la 2-undécyl-4-
hydroxyméthyl-4-méthyl- 1,3 -oxazoline, de la 2-undécyl-4,4-diméthyl-l,3-oxazoline, de la (E)-4,4-diméthyl-2-heptadéc-8-ényl- 1,3 -oxazoline, de la 4-hydroxyméthyl-4-méthyl- 2-heptadécyl- 1,3 -oxazoline, la (E)-4-hydroxyméthyl-4-méthyl-2-heptadéc-8-ényl-l,3- oxazoline, la 2-undécyl-4-éthyl-4-hydroxyméthyl- 1,3 -oxazoline. Avantageusement, la 5 dite oxazoline est la 2-undécyl-4,4-diméthyl-l,3-oxazoline, appelée OX100, de formule:According to an advantageous embodiment of the present invention, said oxazoline is a type 1 oxazoline selected from the group consisting of 2-undecyl-4- hydroxymethyl-4-methyl-1,3-oxazoline, 2-undecyl-4,4-dimethyl-1,3-oxazoline, (E) -4,4-dimethyl-2-heptadec-8-enyl- 1,3-oxazoline, 4-hydroxymethyl-4-methyl-2-heptadecyl- 1,3-oxazoline, (E) -4-hydroxymethyl-4-methyl-2-heptadec-8-enyl-1,3 - oxazoline, 2-undecyl-4-ethyl-4-hydroxymethyl-1,3-oxazoline. Advantageously, the so-called oxazoline is 2-undecyl-4,4-dimethyl-1,3-oxazoline, called OX100, of formula:
De nombreuses voies de synthèse sont connues pour préparer les composés oxazolines selon l'invention. Ainsi, celles-ci peuvent être préparées par synthèseMany synthetic routes are known for preparing the oxazoline compounds according to the invention. Thus, these can be prepared by synthesis
10. chimique en faisant réagir un acide gras (ou un ester méthylique) et un amino-alcool, le plus souvent en présence d'un agent azéotropique afin de favoriser l'élimination de l'eau formée (et du méthanol formé). Une autre voie de -synthèse possible consiste à condenser un halo-amide en présence d'une base forte ou de carbonate de sodium (R. M. Lusskin, J. Amer. Chem. Soc, 72, (1950), 5577). Les oxazolines peuvent également10. chemical by reacting a fatty acid (or a methyl ester) and an amino alcohol, most often in the presence of an azeotropic agent in order to promote the elimination of the water formed (and of the methanol formed). Another possible route of synthesis consists in condensing a halo-amide in the presence of a strong base or of sodium carbonate (R. M. Lusskin, J. Amer. Chem. Soc, 72, (1950), 5577). Oxazolines can also
15 être synthétisées par réaction des époxydes sur les nitriles, par réaction du chlorure de thionyle sur les hydroxyamides ou encore, par action d'un acide sur une aziridinylphosphine.15 be synthesized by reaction of epoxides on nitriles, by reaction of thionyl chloride on hydroxyamides or by the action of an acid on an aziridinylphosphine.
Par l'expression « amincissement » ou « lutte contre la surchargé pondérale 20 localisée », on entend selon la présente invention une action permettant d'éviter ou tout au moins de réduire la formation de graisses sous-cutanées telles que décrites précédemment. Cette action se traduit notamment par une diminution des surcharges ou réserves disgracieuses, par un affinement de la silhouette, par une accélération de l'élimination des excédents, par une meilleure définition du contour de corps ou encore 25 une silhouette resculptée.By the expression “thinning” or “fight against localized overweight”, is meant according to the present invention an action making it possible to avoid or at least reduce the formation of subcutaneous fats as described above. This action is reflected in particular by a reduction in unsightly overloads or reserves, by a refinement of the silhouette, by an acceleration of the elimination of surpluses, by a better definition of the body contour or even a resculpted silhouette.
Par méthode de « traitement cosmétique pour lutter contre la surcharge pondérale localisée » on entend, selon la présente invention, la mise en œuvre d'un
traitement cosmétique permettant de mesurer de manière visible l'action décrite ci- dessus.The term “cosmetic treatment for combating localized overweight” means, according to the present invention, the use of a cosmetic treatment making it possible to visibly measure the action described above.
Ainsi, une composition topique comprenant une ou des oxazolines utilisée selon l'invention peut être appliquée sur les zones de la peau susceptibles de former ces surcharges pondérales localisées, à savoir des zones où ces surcharges sont déjà formées ou en cours de formation.Thus, a topical composition comprising one or more oxazolines used according to the invention can be applied to the areas of the skin capable of forming these localized overweight, namely areas where these overloads are already formed or being formed.
La composition cosmétique selon l'invention se caractérise en ce que la concentration en oxazoline est avantageusement comprise entre environ 0,01 et environ 10% en poids, et plus avantageusement entre environ 0,01 et environ 3% en poids, par rapport au poids total de la composition.The cosmetic composition according to the invention is characterized in that the oxazoline concentration is advantageously between approximately 0.01 and approximately 10% by weight, and more advantageously between approximately 0.01 and approximately 3% by weight, relative to the weight total of the composition.
La composition qui permet la mise en oeuvre de l'invention comprend un support cosmétiquement acceptable, c'est à dire un support compatible avec la peau et peut se présenter sous toutes les formes galéniques normalement utilisées pour une application topique, notamment sous forme d'une solution aqueuse, hydroalcoolique ou huileuse, d'une émulsion huile-dans-eau ou eau-dans-huile ou multiple, d'un gel aqueux ou huileux, d'un produit anhydre liquide, pâteux ou solide, d'une dispersion d'huile dans une phase aqueuse à l'aide de sphérules, ces sphérules pouvant être des nanoparticules polymériques telles que les nanosphères et les nanocapsules ou mieux des vésicules lipidiques de type ionique et ou non-ionique, d'un dispositif trans-dermique ou sous toute autre forme pour application topique.The composition which allows the implementation of the invention comprises a cosmetically acceptable support, that is to say a support compatible with the skin and can be in all the galenical forms normally used for a topical application, in particular in the form of an aqueous, hydroalcoholic or oily solution, an oil-in-water or water-in-oil or multiple emulsion, an aqueous or oily gel, a liquid, pasty or solid anhydrous product, a dispersion of oil in an aqueous phase using spherules, these spherules possibly being polymeric nanoparticles such as nanospheres and nanocapsules or better lipid vesicles of ionic and / or nonionic type, of a trans-dermal or sub-dermal device any other form for topical application.
Cette composition peut être plus ou moins fluide et avoir l'aspect d'une crème blanche ou colorée, d'une pommade, d'un lait, d'une lotion, d'un sérum, d'une pâte, d'une mousse ou d'un gel. Elle peut éventuellement être appliquée sur la peau sous forme d'aérosol. Elle peut également se présenter sous forme solide, et par exemple sous forme de stick. Elle peut aussi être appliquée au moyen d'un patch.This composition can be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foam. or a gel. It can optionally be applied to the skin in the form of an aerosol. It can also be in solid form, and for example in the form of a stick. It can also be applied using a patch.
Avantageusement, le milieu cosmétiquement acceptable est une solution huileuse, une émulsion eau-dans-huile, une émulsion huile-dans eau, une microémulsion, un gel huileux, un gel anhydre, une dispersion de vésicules, de microcapsules ou de microparticules, un dispositif trans-dermique
La composition selon l'invention peut contenir également les adjuvants habituels dans le domaine cosmétique, tels que les gélifiants hydrophiles ou lipophiles, les actifs hydrophiles ou lipophiles, les épaississants, les conservateurs, les antioxydants, les solvants, les parfums, les agents chélateurs, les absorbeurs d'odeur, des filtres chimiques ou minéraux, des pigments minéraux, les tensioactifs, les polymères, les huiles de silicone et les matières colorantes. Les quantités de ces différents adjuvants sont celles classiquement utilisées dans les domaines considérés, et par exemple de 0,01 à 20% du poids total de la composition. Ces adjuvants, selon leur nature, peuvent être introduits dans la phase grasse, dans la phase aqueuse, dans les vésicules lipidiques et ou dans les nanoparticules .Advantageously, the cosmetically acceptable medium is an oily solution, a water-in-oil emulsion, an oil-in water emulsion, a microemulsion, an oily gel, an anhydrous gel, a dispersion of vesicles, microcapsules or microparticles, a device transdermal The composition according to the invention can also contain the adjuvants usual in the cosmetic field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, thickeners, preservatives, antioxidants, solvents, perfumes, chelating agents, odor absorbers, chemical or mineral filters, mineral pigments, surfactants, polymers, silicone oils and coloring materials. The amounts of these various adjuvants are those conventionally used in the fields under consideration, and for example from 0.01 to 20% of the total weight of the composition. These adjuvants, depending on their nature, can be introduced into the fatty phase, into the aqueous phase, into the lipid vesicles and or into the nanoparticles.
Lorsque la composition de l'invention est une émulsion, la proportion de la phase grasse peut aller de 5 à 80% en poids, et de préférence de 5 à 50% du poids total de la composition. Les huiles, les émulsionnants et les coémulsionnants utilisés dans la composition sous forme d'émulsion sont choisis parmi ceux classiquement utilisés dans le domaine considéré. L'émulsionnant et le coémulsionnant sont présents, dans la composition, en une proportion allant de 0,3 à 30% en poids, et de préférence de 0,5 à 20% du poids total de la composition.When the composition of the invention is an emulsion, the proportion of the fatty phase can range from 5 to 80% by weight, and preferably from 5 to 50% of the total weight of the composition. The oils, emulsifiers and coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the field under consideration. The emulsifier and the coemulsifier are present in the composition in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% of the total weight of the composition.
Comme huiles utilisables dans les compositions permettant de mettre en œuvre l'invention, on peut citer les huiles minérales, les huiles d'origine végétale (huile d'abricot, huile de tournesol, huile de prune), les huiles d'origine animale, les huiles de synthèse, les huiles siliconées et les huiles fluorées (perfluoropolyéthers). On peut aussi utiliser comme matières grasses des alcools gras (alcool cétylique), des acides gras, des cires (cire d'abeilles).As oils which can be used in the compositions which make it possible to implement the invention, mention may be made of mineral oils, oils of vegetable origin (apricot oil, sunflower oil, plum oil), oils of animal origin, synthetic oils, silicone oils and fluorinated oils (perfluoropolyethers). Fat can also be used as fatty alcohols (cetyl alcohol), fatty acids, waxes (beeswax).
Comme émulsionnants et coémulsionnants utilisables dans l'invention, on peut citer par exemple les esters d'acide gras et de polyéthylène glycol tels que le stéarate de PEG-40, le stéarate de PEG-100, les esters d'acide gras et de polyol tels que le stéarate de glycéryle et le tristéarate de sorbitane.As emulsifiers and coemulsifiers which can be used in the invention, there may be mentioned, for example, fatty acid and polyethylene glycol esters such as PEG-40 stearate, PEG-100 stearate, fatty acid and polyol esters such as glyceryl stearate and sorbitan tristearate.
Comme gélifiants hydrophiles, on peut citer en particulier les polymères carboxyvinyliques (carbomer), les copolymères acryliques tels que les copolymères d'acrylates/alkylacrylates, les polyacrylamides, les polysaccharides, les gommes naturelles et les argiles, et, comme gélifiants lipophiles, on peut citer les argiles
modifiées comme les bentones, les sels métalliques d'acides gras, la silice hydrophobe et les polyethylenes.As hydrophilic gelling agents, mention may in particular be made of carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate / alkyl acrylate copolymers, polyacrylamides, polysaccharides, natural gums and clays, and, as lipophilic gelling agents, quote clays modified such as bentones, metal salts of fatty acids, hydrophobic silica and polyethylenes.
Les modes d'administration, les posologies et les formes galéniques optimales des composés et compositions selon l'invention peuvent être déterminés selon les critères généralement pris en compte dans l'établissement d'un traitement cosmétique, de préférence dermatologique, adapté à un patient comme par exemple le poids corporel du patient, l'excès de graisse constaté, l'aspect du tissu cellulitique, la tolérance au traitement, le type de peau.The optimal modes of administration, the dosages and the galenical forms of the compounds and compositions according to the invention can be determined according to the criteria generally taken into account in the establishment of a cosmetic treatment, preferably dermatological, adapted to a patient as for example the patient's body weight, the excess fat observed, the appearance of the cellulite tissue, the tolerance to treatment, the type of skin.
La composition utilisée selon l'invention peut contenir d'autres actifs à action amincissante comme les lipolytiques et les liporéducteurs tels que décrits en introduction, conduisant à un effet complémentaire ou éventuellement synergique.The composition used according to the invention may contain other active ingredients with a slimming action such as lipolytics and liporeducing agents as described in the introduction, leading to a complementary or possibly synergistic effect.
L'invention concerne ainsi l'utilisation d'oxazolines pour la préparation de compositions topiques utiles pour prévenir et/ou traiter la cellulite et/ou pour favoriser l'amincissement et notamment pour lutter contre la surcharge pondérale localisée, caractérisée en ce que l'on applique, de façon simultanée, séparée ou étalée dans le temps une ou plusieurs oxazolines ainsi qu'un ou plusieurs actifs amincissants de type lipolytique et/ou un ou plusieurs actifs amincissants de type liporéducteur.The invention thus relates to the use of oxazolines for the preparation of topical compositions useful for preventing and / or treating cellulite and / or for promoting thinning and in particular for combating localized overweight, characterized in that one or more oxazolines as well as one or more slimming active agents of lipolytic type and / or one or more slimming active agents of liporeducing type are applied simultaneously, separately or spread over time.
L'actif amincissant de type lipolytique peut être choisi parmi : la caféine, le rhodystérol, la palmitoyl-carnitine, les bioactifs alpha et gamma, l'escine, le ginkgo biloba et la sphingosine. L'actif amincissant de type liporéducteur peut être choisi parmi : l'andiroba, la Garcinia Cambogia, la rutine.The lipolytic type slimming active can be chosen from: caffeine, rhodysterol, palmitoyl-carnitine, bioactives alpha and gamma, escin, ginkgo biloba and sphingosine. The slimming active ingredient of the liporeducing type can be chosen from: andiroba, Garcinia Cambogia, rutin.
On peut également appliquer de façon simultanée, séparée ou étalée dans le temps un ou plusieurs actifs désinfiltrants et/ou veinotoniques en plus de l'application de la composition utilisée selon l'invention. Les actifs désinfiltrants ou veinotoniques peuvent être choisis parmi : le viburnum, le lierre, l'arnica, la pisolle, la pensée sauvage, le Fucus vesiculosus, la ruscus, le ginkgo biloba et l'escine.It is also possible to apply simultaneously, separate or spread over time one or more disinfiltrating and / or veinotonic active agents in addition to the application of the composition used according to the invention. The disinfiltrating or veinotonic active ingredients can be chosen from: viburnum, ivy, arnica, pisolle, wild pansy, Fucus vesiculosus, ruscus, ginkgo biloba and escin.
La composition utilisée selon l'invention peut en outre comprendre d'autres actifs tels que :
- Un extrait dç fleurs sophora japonica: cet extrait est riche en flavonoïdes (anti radicalaire) et en rutine. Cet actif favorise la microcirculation, facilitant et activant le drainage et la désinfiltration dés tissus ;The composition used according to the invention can also comprise other active agents such as: - An extract of sophora japonica flowers: this extract is rich in flavonoids (anti-radical) and rutin. This active ingredient promotes microcirculation, facilitating and activating the drainage and disinfiltration of tissues;
- L'extrait de centella asiatica : Extrait de centella, plante originaire de l'Afrique de l'est et du Madagascar. Cet actif contient des terpènes (asiaticosides, de l'acide asiatica et de l'acide madécassique), aux propriétés drainantes,, désinfiltrantes et raffermissantes sur les tissus. H est notamment utilisé dans les produits amincissants mais aussi dans les produits anti-vergetures, anti-rides et cicatrisants ; 0 à 5% d'extrait de centella peut ainsi être présent dans une composition amincissante ; - « Hydrolyzed Soy Protein » : protéine de soja qui est un élastorégulateur. Ces peptides du soja peuvent être tout peptide obtenu par hydrolyse de protéines extraites du soja, selon des conditions opératoires connues de l'homme du métier, en d'autres termes tout hydrolysat de protéine du soja. Les peptides de soja, qui sont décrits dans la demande de brevet WO 00/19974 sont particulièrement adaptés pour être introduits dans les compositions utilisées dans le cadre de la présente invention. Cet actif permet la restauration des mécanismes de renouvellement cellulaire, active la synthèse des éléments structuraux de la matrice extracellulaire et possède une action restructurante, régénérante et raffermissante ; 0 à 5% de protéine de soja peut ainsi être présent dans une composition amincissante ; - des actifs anti-âge et/ou raffermissant, parmi lesquels on peut citer les furanes d'avocat, le rétinol et ses dérivés, la vitamine C, la vitamine E, le silicium, ou les insaponifiàbles de soja etc... ;- Centella asiatica extract: Centella extract, a plant native to East Africa and Madagascar. This active ingredient contains terpenes (asiaticosides, asiatica acid and madecassic acid), with draining, disinfiltrating and firming properties on the tissues. It is used in particular in slimming products but also in anti-stretch mark, anti-wrinkle and healing products; 0 to 5% of centella extract can thus be present in a slimming composition; - "Hydrolyzed Soy Protein": soy protein which is an elastoregulator. These soy peptides can be any peptide obtained by hydrolysis of proteins extracted from soy, according to operating conditions known to those skilled in the art, in other words any soy protein hydrolyzate. The soy peptides, which are described in patent application WO 00/19974, are particularly suitable for being introduced into the compositions used in the context of the present invention. This active ingredient allows the restoration of cell renewal mechanisms, activates the synthesis of structural elements of the extracellular matrix and has a restructuring, regenerating and firming action; 0 to 5% of soy protein can thus be present in a slimming composition; - anti-aging and / or firming active ingredients, among which mention may be made of avocado furans, retinol and its derivatives, vitamin C, vitamin E, silicon, or soy unsaponifiable matter, etc .;
- des agents lissants, tels que notamment l'AHA ;- smoothing agents, such as in particular AHA;
- des antioxydants ; - des actifs capables de bloquer la différenciation des pré-adipocytes en adipocytes dont notamment des triterpènes, des antagonistes PPARs (Peroxysome Proliferator-Activated Receptor), des inhibiteurs de MMPs notamment l'extrait peptidique de lupin tel que décrit dans la demande de brevet français FR 2 792 202;- antioxidants; active agents capable of blocking the differentiation of pre-adipocytes into adipocytes, in particular triterpenes, PPARs antagonists (Peroxysome Proliferator-Activated Receptor), MMPs inhibitors, in particular the lupine peptide extract as described in the French patent application FR 2,792,202;
- des actifs pour favoriser l'amincissement tel que les isoflavones, notamment les isoflavones décrites dans la demande de brevet français n°0207995 ; etc...
La présente invention a également pour objet une méthode de traitement cosmétique pour favoriser l'amincissement, caractérisée en ce que l'on applique par voie topique une composition cosmétique comprenant une ou plusieurs oxazolines.active ingredients for promoting thinning, such as isoflavones, in particular isoflavones described in French patent application No. 0207995; etc ... The present invention also relates to a cosmetic treatment method for promoting thinning, characterized in that a cosmetic composition comprising one or more oxazolines is applied topically.
Un autre objet de la présente invention est une méthode de traitement cosmétique pour prévenir et/ou traiter la cellulite, caractérisée en ce que l'on applique par voie topique une composition comprenant une ou plusieurs oxazolines.Another object of the present invention is a cosmetic treatment method for preventing and / or treating cellulite, characterized in that a composition comprising one or more oxazolines is applied topically.
Un objet de la présente invention est également une méthode de traitement cosmétique pour affiner la silhouette, accélérer l'élimination des excédents, mieux définir, le contour du corps et/ou resculpter la silhouette, caractérisée en ce que l'on applique par voie topique une composition comprenant une ou plusieurs oxazolines.An object of the present invention is also a cosmetic treatment method for refining the silhouette, accelerating the elimination of excess, better defining, the outline of the body and / or resculpting the silhouette, characterized in that it is applied topically. a composition comprising one or more oxazolines.
La surcharge pondérale se caractérise, dans le cadre de la présente invention, par un surpoids, par rapport au « poids idéal », non pathologique. Le traitement cosmétique selon l'invention permet de perdre ou d'affiner des rondeurs localisées superflues mais ne s'identifie pas à un traitement thérapeutique. Selon une variante avantageuse de l'invention, lors de ces méthodes de traitement cosmétique, on applique par voie topique sur les zones de la peau susceptibles de former des surcharges pondérales localisées, de façon simultanée, préparée ou étalée dans le temps, une ou plusieurs oxazolines ainsi qu'un ou plusieurs actifs amincissants de type lipolytique et/ou liporéducteur, et/ou un ou des actifs désinfiltrants et/ou veinotoniques.Overweight is characterized, in the context of the present invention, by being overweight, relative to the "ideal weight", not pathological. The cosmetic treatment according to the invention makes it possible to lose or refine superfluous localized curves but is not identified with a therapeutic treatment. According to an advantageous variant of the invention, during these cosmetic treatment methods, one or more is applied topically to the areas of the skin liable to form localized overweight, simultaneously, prepared or spread over time. oxazolines as well as one or more slimming active agents of lipolytic and / or liporeductive type, and / or one or more disinfiltrating and / or venotonic active agents.
Les figures 1 et 2 illustrent l'effet de l'OXlOO sur l'incorporation d'acétate radio- marqué dans les lipides adipocytaires. Les résultats sont exprimés en pourcentage du témoin et représentent l'incorporation d' acétate radiomarqué.Figures 1 and 2 illustrate the effect of OXlOO on the incorporation of radiolabelled acetate into adipocyte lipids. The results are expressed as a percentage of the control and represent the incorporation of radiolabelled acetate.
Les exemples suivant illustrent la présente invention.
Exemple 1 : crème huile dans eauThe following examples illustrate the present invention. Example 1: oil in water cream
QS = quantité suffisante QSP = quantité suffisante poux
Exemple 2 : crème eau dans huileQS = sufficient quantity QSP = sufficient quantity lice Example 2: water in oil cream
QS = quantité suffisante QSP = quantité suffisante pour
QS = sufficient quantity QSP = sufficient quantity for
Exemple 3 : stickExample 3: stick
QS = quantité suffisanteQS = sufficient quantity
QSP = quantité suffisante pour
QSP = sufficient quantity for
Exemple 4 : gel crèmeEXAMPLE 4 Cream Gel
QS = quantité suffisante QSP = quantité suffisante pour
QS = sufficient quantity QSP = sufficient quantity for
Exemple 5 : sprayExample 5: spray
QS = quantité suffisante QSP = quantité suffisante pourQS = sufficient quantity QSP = sufficient quantity for
Exemple 6 : Evaluation de la synthèse lipidique dans des adipocytes en suspensionEXAMPLE 6 Evaluation of the Lipid Synthesis in Suspended Adipocytes
Produit à l'essaiTest product
Une solution d'OXlOO, diluée à une concentration de 10 Λ-"2^ M dans du DMSO, a été testée.A solution of OXlOO, diluted to a concentration of 10 " - " 2 ^ M in DMSO, was tested.
Conditions de cultureCulture conditions
Des adipocytes humains normaux ont été isolés à partir de biopsies abdominalesNormal human adipocytes have been isolated from abdominal biopsies
(chirurgie plastique). Immédiatement après la réception, les prélèvements sont incubés pendant 30 minutes à 37°C en présence de collagénase (fournie par la société Sigma).(plastic surgery). Immediately after receipt, the samples are incubated for 30 minutes at 37 ° C in the presence of collagenase (supplied by the company Sigma).
La suspension d' adipocytes est ensuite rincée et diluée trois fois dans le milieu de culture. Le milieu de culture est constitué de :The suspension of adipocytes is then rinsed and diluted three times in the culture medium. The culture medium consists of:
- 1,87 mg/ml bicarbonate (fourni par la société Life Technologies),- 1.87 mg / ml bicarbonate (supplied by the company Life Technologies),
- 25 UI/ml/ 25μg/ml de pénicilline/streptomycine (fournis par la société Life Technologies),- 25 IU / ml / 25μg / ml of penicillin / streptomycin (supplied by the company Life Technologies),
- 2 mM de glutamine (fourni par la société Life Technologies), - 100% v/v.de MEM (fourni par la société Merck Eurolab), et- 2 mM glutamine (supplied by the company Life Technologies), - 100% v / v . MEM (supplied by Merck Eurolab), and
- 0,5% p/v d'albumine d'origine bovine (fourni par la société Sigma).
Evaluation de la synthèse lipidique- 0.5% w / v of albumin of bovine origin (supplied by the company Sigma). Assessment of lipid synthesis
Les adipocytes en suspension sont incubés pendant 1 heure à 37°C en présence de différentes concentrations d'OXlOO. Les concentrations en OX100 testées sont deThe adipocytes in suspension are incubated for 1 hour at 37 ° C. in the presence of different concentrations of OXlOO. The OX100 concentrations tested are
20 μM, 4 μM et 0,8 μM. Un volume de 10 ml d'acétate radio-marqué (2-C14, 60,87 μCi ml, fourni par la société20 μM, 4 μM and 0.8 μM. A volume of 10 ml of radiolabelled acetate (2-C 14 , 60.87 μCi ml, supplied by the company
Amersham) est ensuite ajouté à la préparation.Amersham) is then added to the preparation.
Après 4 heures d'incubation, les lipides sont extraits selon la procédure décrite parAfter 4 hours of incubation, the lipids are extracted according to the procedure described by
Bligh et Dyer, Can J Biochem Physiol, 37, 922, (1959), (méthanol/chloroforme/eau), évaporés sous azote et la radio-activité incorporée a été quantifiée par scintillation liquide (appareil de scintillation liquide de référence LKB 1210, fourni par la sociétéBligh and Dyer, Can J Biochem Physiol, 37, 922, (1959), (methanol / chloroform / water), evaporated under nitrogen and the incorporated radioactivity was quantified by liquid scintillation (reference liquid scintillation apparatus LKB 1210, provided by the company
Rackbeta).Rackbeta).
L'éventuelle interaction entre l'acétate radio-marqué et l'OXlOO a été évaluée afin de confirmer la spécificité du marquage, en incubant la plus forte concentration d'OXlOOThe possible interaction between radiolabelled acetate and OXlOO was evaluated in order to confirm the specificity of the labeling, by incubating the highest concentration of OXlOO
(20 μM) avec de l'acétate seul.(20 μM) with acetate alone.
RésultatsResults
L'OXlOO n'induit aucune interférence avec le radio-marquage.The OXlOO does not induce any interference with radiolabelling.
Après 4 heures d'incubation, l'incorporation de C14 était élevée dans les adipocytes contrôles (185 000 cpm). Le bruit de fond à T0 était faible. La molécule de référence, la céraline (inhibiteur de FAS, Fatty Acid Synthase) testée àAfter 4 hours of incubation, the incorporation of C 14 was high in the control adipocytes (185,000 cpm). The background noise at T0 was low. The reference molecule, ceralin (FAS inhibitor, Fatty Acid Synthase) tested at
10 μM inhibe l'incoφoration d'acétate (95% d'inhibition/témoin). Ce résultat valide l'essai.10 μM inhibits the incoφoration of acetate (95% inhibition / control). This result validates the test.
L'OXlOO à 20 et 4 μM diminue l'incoφoration d'acétate de respectivement 31 et 25% du témoin (figure 1) On a montré de manière tout à fait inattendue que l'OXlOO est capable d'inhiber la lipogénèse dans des adipocytes humains.OXlOO at 20 and 4 μM reduces acetate incoφoration by 31 and 25% respectively of the control (FIG. 1) It has been shown quite unexpectedly that OXlOO is capable of inhibiting lipogenesis in adipocytes humans.
Exemple 7 : Evaluation de la synthèse lipidique dans des adipocytes en suspensionEXAMPLE 7 Evaluation of the Lipid Synthesis in Suspended Adipocytes
Produit à l'essaiTest product
Une solution d'OXlOO (10'2 M dans du DMSO) a été testée.A solution of OXlOO (10 '2 M in DMSO) was tested.
Conditions de culture : elles sont identiques à celle de l'exemple 6
Evaluation de la synthèse lipidiqueCulture conditions: they are identical to that of Example 6 Assessment of lipid synthesis
Les adipocytes en suspension sont incubés pendant lh à 37°C en présence de différentes concentrations d'OXlOO (10, 20 et 100 μM). Un volume de 10 ml d'acétate radio- marqué (2-C14, 60,87 μCi/ml, Amersham) est ensuite ajouté à la préparation. Après 4h d'incubation, les lipides sont extraits selon la procédure décrite par Bligh et Dyer (méthanol/chloroforme/eau), évaporés sous azote et la radio-activité incoφorée a été quantifiée par scintillation liquide (LKB 1210 Rackbeta).The adipocytes in suspension are incubated for 1 h at 37 ° C. in the presence of different concentrations of OX100 (10, 20 and 100 μM). A volume of 10 ml of radiolabelled acetate (2-C 14 , 60.87 μCi / ml, Amersham) is then added to the preparation. After 4 hours of incubation, the lipids are extracted according to the procedure described by Bligh and Dyer (methanol / chloroform / water), evaporated under nitrogen and the incoφorated radioactivity was quantified by liquid scintillation (LKB 1210 Rackbeta).
Résultats L' OX100 n'induit aucune interférence avec le radio-marquage.Results The OX100 does not induce any interference with radiolabelling.
La molécule de référence, la céraline (inhibiteur de FAS, Fatty Acid Synthase) testée àThe reference molecule, ceralin (FAS inhibitor, Fatty Acid Synthase) tested at
10 μM inhibe Pincoφoration d'acétate (75% d'inhibition/témoin). Ce résultat valide l'essai.10 μM inhibits the incorporation of acetate (75% inhibition / control). This result validates the test.
L'OXlOO testé à 10, 20 et 100 μM diminue significativement l'incoφoration d'acétate dans les lipides (respectivement 35, 3.8 et 39% du témoin ; figure 2).The OXlOO tested at 10, 20 and 100 μM significantly reduces the incoφoration of acetate in the lipids (respectively 35, 3.8 and 39% of the control; FIG. 2).
L'OXlOO a montré une activité inhibitrice significative de la synthèse des lipides. L'OXlOO est donc capable d'inhiber la lipogénèse dans des adipocytes humains en culture.
OXlOO has shown significant inhibitory activity on lipid synthesis. OXlOO is therefore capable of inhibiting lipogenesis in human adipocytes in culture.
Claims
1. Utilisation cosmétique d'une composition comprenant au moins une oxazoline, à titre de principe actif, comme amincissant.1. Cosmetic use of a composition comprising at least one oxazoline, as active principle, as a slimming agent.
2. Utilisation cosmétique d'une composition comprenant au moins une oxazoline, à titre de principe actif, pour prévenir et/ou traiter la cellulite.2. Cosmetic use of a composition comprising at least one oxazoline, as active ingredient, for preventing and / or treating cellulite.
3. Utilisation cosmétique selon l'une quelconque des revendications 1 ou 2 caractérisée en ce que ladite oxazoline répond aux formules générales suivantes:3. Cosmetic use according to any one of claims 1 or 2 characterized in that said oxazoline corresponds to the following general formulas:
Type 1Type 1
Type 2 Type 2
Type 3 dans laquelle Ri représente un groupe alkyle en Cι-C4o, linéaire ou ramifié, saturé ou insaturé, comprenant éventuellement une ou plusieurs insaturation(s) éfhylénique(s) ainsi que un ou plusieurs substituant(s) choisi(s) dans le groupe formé par les radicaux hydroxy (OH) et alcoxy en Cι-C6 (OCι-C6) ;Type 3 in which Ri represents a Cι-C 4 o alkyl group, linear or branched, saturated or unsaturated, optionally comprising one or more ethylenic unsaturation (s) as well as one or more substituent (s) chosen (s) from the group formed by hydroxyl (OH) and alkoxy, Cι-C 6 (OCι-C 6);
R2, R3, R-. et R5 représentent, de manière indépendante, un atome d'hydrogène, un radical hydroxy, ou un groupe alkyle en Cι-C30, linéaire ou ramifié, saturé ou insaturé, comprenant éventuellement une ou plusieurs insaturations éthyléniques ainsi que un ou plusieurs substituant(s) choisi(s) dans le groupe formé par les radicaux hydroxy (OH), alcoxy en Cι-C6 (OCι-C6) et alcoxy en Cι-C6 carbonyles (COOCι-C6).R 2 , R 3 , R-. and R 5 represent, independently, a hydrogen atom, a hydroxy radical, or a Cι-C 30 alkyl group, linear or branched, saturated or unsaturated, optionally comprising one or more ethylenic unsaturations as well as one or more substituents (s) chosen (s) from the group formed by hydroxyl (OH), alkoxy, Cι-C 6 (OCι-C 6) alkoxy Cι-C 6 carbonyl (COOCι-C 6).
4. Utilisation cosmétique selon l'une quelconque des revendications précédentes, caractérisée en ce que ladite oxazoline est une oxazoline de type 1 sélectionnée dans le groupe composé de la 2-undécyl-4-hydroxyméthyl-4-méthyl- 1,3 -oxazoline, de la 2- undécyl-4,4-diméthyl- 1,3 -oxazoline, de la (E)-4,4-diméthyl-2-heptadéc-8-ényl-l,3- oxazoline, de la 4-hydroxyméthyl-4-méthyl-2-heptadécyl- 1,3 -oxazoline, la (E)-4- hydroxyméthyl-4-méthyl-2-heptadéc-8-ényl- 1 ,3-oxazoline, la 2-undécyl-4-éthyl-4- hydroxyméthyl- 1,3 -oxazoline.4. Cosmetic use according to any one of the preceding claims, characterized in that said oxazoline is a type 1 oxazoline selected from the group consisting of 2-undecyl-4-hydroxymethyl-4-methyl-1,3-oxazoline, 2- undecyl-4,4-dimethyl-1,3-oxazoline, (E) -4,4-dimethyl-2-heptadec-8-enyl-1,3-oxazoline, 4-hydroxymethyl- 4-methyl-2-heptadecyl-1,3-oxazoline, (E) -4- hydroxymethyl-4-methyl-2-heptadec-8-enyl- 1, 3-oxazoline, 2-undecyl-4-ethyl- 4-hydroxymethyl-1,3-oxazoline.
5. Utilisation cosmétique selon l'une quelconque des revendications précédentes, caractérisée en ce que ladite oxazoline est la 2-undécyl-4,4-diméthyl- 1,3 -oxazoline, appelée OX100, de formule: 5. Cosmetic use according to any one of the preceding claims, characterized in that said oxazoline is 2-undecyl-4,4-dimethyl-1,3-oxazoline, called OX100, of formula:
6. Utilisation selon l'une quelconque des revendications précédentes, caractérisée en ce que la composition comprend entre 0,01 et 10% en poids d'oxazoline, avantageusement entre 0,01 et 3% en poids d'oxazoline, par rapport au poids total de la composition et un milieu cosmétiquement acceptable.6. Use according to any one of the preceding claims, characterized in that the composition comprises between 0.01 and 10% by weight of oxazoline, advantageously between 0.01 and 3% by weight of oxazoline, relative to the weight total of the composition and a cosmetically acceptable medium.
7. Utilisation cosmétique selon l'une quelconque des revendications précédentes, caractérisée en ce que l'on applique, de façon simultanée, séparée ou étalée dans le temps, une ou plusieurs oxazolines ainsi que un ou plusieurs actifs amincissants de type lipolytique et/ou à un ou plusieurs actifs amincissants de type liporéducteur.7. Cosmetic use according to any one of the preceding claims, characterized in that one, simultaneously, separately or spread over time, is applied one or more oxazolines as well as one or more slimming active agents of lipolytic type and / or to one or more slimming active ingredients of the liporeducing type.
8. Utilisation selon l'une quelconque des revendications précédentes, caractérisée en ce que l'on applique en outre de façon simultanée, séparée ou étalée dans le temps, un ou plusieurs actifs désinfiltrants et/ou veinotoniques.8. Use according to any one of the preceding claims, characterized in that one also applies simultaneously, separately or spread over time, one or more disinfiltrating and / or veinotonic active agents.
9. Utilisation cosmétique selon l'une quelconque des revendications précédentes, caractérisée en ce que la composition est à application topique.9. Cosmetic use according to any one of the preceding claims, characterized in that the composition is for topical application.
10. Méthode de traitement cosmétique pour favoriser l'amincissement, caractérisée en ce que l'on applique par voie topique une composition cosmétique comprenant une ou plusieurs oxazolines.10. Cosmetic treatment method for promoting thinning, characterized in that a cosmetic composition comprising one or more oxazolines is applied topically.
11. Méthode de traitement cosmétique pour prévenir et/ou traiter la cellulite, caractérisée en ce que l'on applique par voie topique une composition comprenant une ou plusieurs oxazolines.11. Cosmetic treatment method for preventing and / or treating cellulite, characterized in that a composition comprising one or more oxazolines is applied topically.
12. Méthode de traitement cosmétique pour affiner la silhouette, accélérer l'élimination des excédents, mieux définir le contour du coφs et/ou resculpter la silhouette, caractérisée en ce que l'on applique par voie topique une composition comprenant une ou plusieurs oxazolines.12. Cosmetic treatment method to refine the silhouette, accelerate the elimination of excess, better define the contour of the cost and / or resculpt the silhouette, characterized in that a composition comprising one or more oxazolines is applied topically.
13. Méthode de traitement cosmétique selon l'une quelconque des revendications 10 à 12, caractérisée en ce que l'on applique par voie topique sur les zones de la peau susceptibles de former des surcharges pondérales localisées, de façon simultanée, séparée ou étalée dans le temps, une ou plusieurs oxazolines ainsi qu'un ou des actifs amincissants de type lipolytique et/ou liporéducteur et/ou un ou des actifs désinfiltrants et/ou veinotoniques. 13. Cosmetic treatment method according to any one of claims 10 to 12, characterized in that one applies topically to the areas of the skin liable to form localized overweight, simultaneously, separately or spread over over time, one or more oxazolines as well as one or more slimming active agents of the lipolytic and / or liporeducing type and / or one or more disinfiltrating and / or venotonic active agents.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0307333A FR2856294B1 (en) | 2003-06-18 | 2003-06-18 | COSMETIC USE OF A COMPOSITION COMPRISING AT LEAST ONE OXAZOLIN AS AN ACTIVE INGREDIENT, AS SLIMMING AND / OR FOR PREVENTING AND / OR TREATING CELLULITE |
| PCT/FR2004/001504 WO2004112741A1 (en) | 2003-06-18 | 2004-06-17 | Cosmetic use of a composition containing at least one oxazoline, serving as an active substance, as a slimming product and/or for preventing and/or treating cellulite |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1648569A1 true EP1648569A1 (en) | 2006-04-26 |
| EP1648569B1 EP1648569B1 (en) | 2006-12-06 |
Family
ID=33484527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP04767366A Expired - Lifetime EP1648569B1 (en) | 2003-06-18 | 2004-06-17 | Cosmetic use of a composition containing at least one oxazoline, serving as an active substance, as a slimming product and/or for preventing and/or treating cellulite |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7629371B2 (en) |
| EP (1) | EP1648569B1 (en) |
| AT (1) | ATE347401T1 (en) |
| DE (1) | DE602004003587T2 (en) |
| ES (1) | ES2276339T3 (en) |
| FR (1) | FR2856294B1 (en) |
| HK (1) | HK1091151A1 (en) |
| WO (1) | WO2004112741A1 (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10343851A1 (en) * | 2003-09-23 | 2005-04-14 | Beiersdorf Ag | Sprayable cosmetic formulation |
| US9089576B2 (en) | 2004-04-30 | 2015-07-28 | Laboratoires Expanscience | Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency or oxidative stress or skin ageing or dry skin |
| DE602005027563D1 (en) * | 2004-05-28 | 2011-06-01 | Expanscience Lab | USE OF FURANAL CYLINDERS FOR COSMETIC TREATMENT OF CELLULITIS |
| FR2870740B1 (en) * | 2005-03-21 | 2008-06-13 | Expanscience Sa Lab | USE OF ALKYL FURANS FOR THE COSMETIC TREATMENT OF CELLULITE |
| FR2870742B1 (en) | 2004-05-28 | 2008-03-14 | Expanscience Laboratoires Sa | USE OF ALKYL FURANS FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF DIABETES, OBESITY AND FOR THE COSMETIC TREATMENT OF CELLULITE AND OVERLOAD |
| PL1750695T3 (en) * | 2004-05-28 | 2010-08-31 | Expanscience Lab | Use of furan alkyls for preparing a drug for treating obesity and cosmetically treating overweight |
| FR2870743B1 (en) * | 2005-03-21 | 2012-03-09 | Expanscience Lab | USE OF ALKYL FURANS FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF OBESITY AND FOR THE COSMETIC TREATMENT OF THE WEST OVERLOAD |
| FR2885128B1 (en) * | 2005-04-27 | 2007-07-06 | Expanscience Laboratoires Sa | DEPIGMENTING OR LIGHTENING COSMETIC COMPOSITION COMPRISING AT LEAST ONE OXAZOLINE AS AN ACTIVE INGREDIENT DEPIGMENTING OR LIGHTENING |
| FR2886546B1 (en) * | 2005-06-03 | 2007-08-24 | Henri Lazarini | COMPOSITION BASED ON PLANT EXTRACTS USEFUL IN COSMETICS AND PHARMACOLOGY, IN PARTICULAR AS SLIMMING AGENT |
| FR2948565B1 (en) | 2009-07-30 | 2011-10-28 | Expanscience Lab | COSMETIC COMPOSITION FOR THE TREATMENT OF ACNE COMPRISING A PETIDIC EXTRACT FROM SCHIZANDRA |
| FR2948566B1 (en) | 2009-07-30 | 2012-08-10 | Expanscience Lab | EXTRACT OF SCHIZANDRA SPHENANTHERA FRUIT AND COSMETIC, DERMATOLOGICAL AND NUTRACEUTICAL COMPOSITIONS COMPRISING SAME |
| FR2953136B1 (en) | 2009-11-30 | 2012-05-11 | Expanscience Lab | EXTRACT OF VIGNA UNGUICULATA SEEDS AND COSMETIC, PHARMACEUTICAL, DERMATOLOGICAL, NUTRACEUTICAL OR FOOD COMPOSITIONS COMPRISING THE SAME |
| FR2953135B1 (en) | 2009-11-30 | 2012-05-11 | Expanscience Lab | MACROSTACHYA ACACIA SEED EXTRACT AND COSMETIC, PHARMACEUTICAL, DERMATOLOGICAL, NUTRACEUTICAL OR FOOD COMPOSITIONS COMPRISING THE SAME |
| EP2368972B1 (en) * | 2010-03-23 | 2013-05-15 | Cognis IP Management GmbH | Eudermic manual dishwashing composition |
| FR2969496B1 (en) | 2010-12-22 | 2013-11-08 | Expanscience Lab | EXTRACT OF PULP AND / OR AVOCADO SKIN RICH IN POLYPHENOLS AND COSMETIC, DERMATOLOGICAL AND NUTRACEUTICAL COMPOSITIONS COMPRISING SAME |
| FR2969495B1 (en) | 2010-12-22 | 2013-10-11 | Expanscience Lab | EXTRACT OF MACA-RICH AERIAL PARTS OF POLYPHENOLS AND COMPOSITION COMPRISING THE SAME |
| US20120276030A1 (en) * | 2011-04-29 | 2012-11-01 | Garden Art Innovations, Llc | Cosmetic composition |
| FR2975004B1 (en) | 2011-05-13 | 2013-06-28 | Expanscience Lab | NEW ANTI-REDNESS ACTIVE INGREDIENTS AND COSMETIC COMPOSITIONS COMPRISING THE SAME |
| FR2999429B1 (en) | 2012-12-18 | 2015-01-02 | Expanscience Lab | EXTRACT OF PASSIFLORE SEEDS AND COSMETIC, PHARMACEUTICAL, DERMATOLOGICAL OR NUTRACEUTICAL COMPOSITIONS COMPRISING SAME |
| FR3001889B1 (en) | 2013-02-11 | 2021-02-12 | Expanscience Lab | USE OF A COMPOSITION CONTAINING AVOCADO PERSEOSE IN THE PROTECTION OF EPIDERMAL STEM CELLS. |
| FR3011008B1 (en) | 2013-09-24 | 2017-12-29 | Expanscience Lab | METHODS OF EVALUATING DELETER EFFECTS OF UV ON CHILD'S SKIN |
| FR3010906B1 (en) | 2013-09-25 | 2016-12-23 | Expanscience Lab | LIPID EXTRACT OF PASSIFLOWER SEEDS |
| FR3016373B1 (en) | 2014-01-10 | 2018-01-19 | Laboratoires Expanscience | MAMMELON SKIN MODEL RECONSTITUTES |
| FR3028764B1 (en) | 2014-11-26 | 2016-12-09 | Expanscience Lab | PEPTIDE AND OSIDIC FRUIT EXTRACT OF SCHIZANDRA AND IMPROVEMENT OF THE NEUROSENSORY SKIN SYSTEM RESPONSE |
| EP3574899A1 (en) * | 2018-05-28 | 2019-12-04 | Université de Bourgogne | Oleic acid derivatives, pharmaceutical composition or food composition comprising said oleic acid derivatives, and their uses |
| FR3098394B1 (en) | 2019-07-12 | 2022-07-08 | Expanscience Lab | Composition comprising at least one oxazoline for inhibiting the growth of yeast of the genus Malassezia involved in particular in cradle cap |
| FR3098405B1 (en) | 2019-07-12 | 2021-06-25 | Expanscience Lab | Composition comprising passionflower seed polyphenols, avocado peptides and witch hazel extract and use to treat and / or prevent stretch marks |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2368075A (en) * | 1943-09-11 | 1945-01-23 | Commercial Solvents Corp | Astringent preparations |
| US4876249A (en) * | 1987-01-12 | 1989-10-24 | Rajadhyaksha Vithal J | Compositions and method comprising heterocyclic compounds containing two heteroatoms |
| JPH1017565A (en) * | 1996-06-26 | 1998-01-20 | Sankyo Co Ltd | Oxazoline compound |
| CA2323179A1 (en) * | 1998-03-16 | 1999-09-23 | The Procter & Gamble Company | Method of reducing cellulite in mammalian skin |
| FR2784029B1 (en) | 1998-10-05 | 2001-01-05 | Pharmascience Lab | METHOD FOR THE PREVENTION AND / OR COSMETIC TREATMENT OF STRETCH MARKS AND USE IN DERMATOLOGY |
| FR2792202B1 (en) | 1999-04-19 | 2003-06-13 | Pharmascience Lab | LUPINE PEPTIDE EXTRACT AND PHARMACEUTICAL OR COSMETIC OR NUTRACEUTICAL COMPOSITION COMPRISING SUCH EXTRACT |
| JP2002338555A (en) * | 2001-05-23 | 2002-11-27 | Ono Pharmaceut Co Ltd | Butanoic acid derivative |
| FR2834216B1 (en) | 2001-12-27 | 2004-04-30 | Pharmascience Lab | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE OXAZOLINE FOR INHIBITING LANGERHAN CELL MIGRATION, AND USES THEREOF |
| FR2841470B1 (en) | 2002-06-27 | 2006-01-13 | Pharmascience Lab | USE OF ISOFLAVONES FOR THE PREPARATION OF TOPICAL COMPOSITIONS USEFUL FOR PROMOTING SLIMMING AND ASSOCIATED COSMETIC TREATMENT METHOD |
-
2003
- 2003-06-18 FR FR0307333A patent/FR2856294B1/en not_active Expired - Fee Related
-
2004
- 2004-06-17 DE DE602004003587T patent/DE602004003587T2/en not_active Expired - Lifetime
- 2004-06-17 WO PCT/FR2004/001504 patent/WO2004112741A1/en active IP Right Grant
- 2004-06-17 ES ES04767366T patent/ES2276339T3/en not_active Expired - Lifetime
- 2004-06-17 AT AT04767366T patent/ATE347401T1/en not_active IP Right Cessation
- 2004-06-17 US US10/561,173 patent/US7629371B2/en active Active
- 2004-06-17 EP EP04767366A patent/EP1648569B1/en not_active Expired - Lifetime
-
2006
- 2006-10-18 HK HK06111407A patent/HK1091151A1/en not_active IP Right Cessation
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2004112741A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1091151A1 (en) | 2007-01-12 |
| US7629371B2 (en) | 2009-12-08 |
| FR2856294A1 (en) | 2004-12-24 |
| EP1648569B1 (en) | 2006-12-06 |
| WO2004112741A1 (en) | 2004-12-29 |
| DE602004003587T2 (en) | 2007-10-25 |
| ES2276339T3 (en) | 2007-06-16 |
| US20060122246A1 (en) | 2006-06-08 |
| FR2856294B1 (en) | 2005-08-05 |
| ATE347401T1 (en) | 2006-12-15 |
| DE602004003587D1 (en) | 2007-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1648569B1 (en) | Cosmetic use of a composition containing at least one oxazoline, serving as an active substance, as a slimming product and/or for preventing and/or treating cellulite | |
| CA2312528C (en) | Cosmetic toning compound containing at least one hydroxystilbene in association with ascorbic acid | |
| FR2671487A1 (en) | USE OF A GROWTH FACTOR IN A SLIMMING COMPOSITION. | |
| EP0655235B1 (en) | Slimming composition | |
| EP1515696B1 (en) | Use of isoflavones for promoting slimming | |
| FR2855057A1 (en) | Cosmetic or dermatological slimming composition, also effective against cellulite or orange-peel skin, contains cafestol, kahweol or derived diterpene | |
| FR2884418A1 (en) | USE OF A PEPTIDE AS A SLIMMING ACTIVE INGREDIENT | |
| FR2848846A1 (en) | COSMETIC USE OF ASCORBIC ACID DERIVATIVES AS BLANCHING AGENTS | |
| EP1811953B1 (en) | Novel use of chaulmoogra oil and guggulipids in therapeutics and cosmetics | |
| EP1676606A1 (en) | Slimming composition comprising a xanthin base, a dimethicone copolyol and a polyurethane powder | |
| WO2007135268A2 (en) | Use of peptides as active slimming ingredients | |
| FR2862533A1 (en) | Topically applied slimming agent, useful e.g. for combating cellulite or orange-peel skin, containing activator of cellular interleukin 11 production, preferably hydroxy-stilbene derivative | |
| FR2926021A1 (en) | Cosmetic use of a C-glycoside derivative e.g. as an agent acting on the microcirculation and for the preparation of a composition to stimulate dermal blood circulation and/or for preventing insufficiency of superficial venous system | |
| CA2663697C (en) | Use of quinoa extract as cosmetic and pharmaceutic slimming agent and/or as an agent preventing the formation of new fats in the human body | |
| WO2003035023A1 (en) | Cosmetic composition containing a dhea derivative and a soothing agent | |
| CA2467734A1 (en) | Composition based on diosgenin ester for topical use | |
| FR2758724A1 (en) | Controlling cellulite and fat deposition | |
| WO2003009826A1 (en) | Use of steroids as slimming agents | |
| FR2858769A1 (en) | Cosmetic, dermatological and/or pharmaceutical compositions, especially for combating skin aging and/or protecting skin, containing peptide including arginine-glycine-serine moiety as active agent | |
| FR2876909A1 (en) | Cosmetic and/or pharmaceutical composition, to prevent or treat adipose overloads and cellulitis, comprises a combination of one or more xanthinic bases and chaulmoogra oil and/or its components | |
| FR2876908A1 (en) | Use of chaulmoogra oil, or its components, for treatment or prevention of excess fat and cellulitis, acts by inducing lipolysis | |
| FR2849594A1 (en) | Cosmetic use of zardaverine as slimming agent, for preventing and/or treating cellulite or orange-peel skin and/or improving contours of face | |
| FR2879099A1 (en) | Cosmetic or dermatological composition, useful to fight against the cellulites and/or the orange peel, and to treat or prevent obesity or lipid disorder, comprises concentrated glycoproteins from soft almond | |
| FR3126870A1 (en) | Pharmaceutical or cosmetic composition intended to improve cellulite and varicose veins, characterized in that it comprises a combination of theanine and polysaccharides derived from matcha. | |
| WO2002080877A2 (en) | Use of alverine or one of its salts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20051219 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| DAX | Request for extension of the european patent (deleted) | ||
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061206 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061206 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061206 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061206 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061206 Ref country code: IE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061206 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061206 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061206 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061206 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061206 |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20061218 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: FRENCH |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1091151 Country of ref document: HK |
|
| REF | Corresponds to: |
Ref document number: 602004003587 Country of ref document: DE Date of ref document: 20070118 Kind code of ref document: P |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070306 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070306 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070507 |
|
| NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1091151 Country of ref document: HK |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2276339 Country of ref document: ES Kind code of ref document: T3 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20070907 |
|
| BERE | Be: lapsed |
Owner name: LABORATOIRES EXPANSCIENCE Effective date: 20070630 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070630 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070630 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070307 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061206 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080630 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080630 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061206 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070617 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061206 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070607 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20140617 Year of fee payment: 11 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20140610 Year of fee payment: 11 Ref country code: IT Payment date: 20140619 Year of fee payment: 11 Ref country code: ES Payment date: 20140613 Year of fee payment: 11 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602004003587 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150617 |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20150617 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150617 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160101 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20160906 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150618 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230512 Year of fee payment: 20 |